By Paul Tullis — 2021
Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.
Read on www.nature.com
CLEAR ALL
Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.
These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.
2
The first randomized controlled trial to compare the illicit psychedelic psilocybin with a conventional selective serotonin reuptake inhibitor (SSRI) antidepressant found that the former improved symptoms of depression just as well on an established metric—and had fewer side effects.
1
Study participants at some of the country's leading medical research centers are going through intense therapy and six-hour psychedelic journeys deep into their minds to do things like quit smoking and worry less.
The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder (MDD).
While we can now begin to glimpse an end to the drug war, it is much harder to envision what the drug peace will look like. How will we fold these powerful substances into our society and our lives so as to minimize their risks and use them most constructively?
A new review of studies finds that LSD, psilocybin, and MDMA hold potential for treating mental illness.
Now, as a handful of patients and more recently doctors and therapists have been granted exemptions to use psilocybin, the nation’s federal health agency is considering making changes to existing policies that could open the door to much more than magic mushrooms.
Williams is the co-lead author of a recent retrospective study that found those who tried doses of psilocybin (more commonly known as magic mushrooms), LSD, or MDMA (the pure substance found in Ecstasy or Molly) reported a decrease in trauma symptoms, depression and anxiety after 30 days.
Roland Griffiths' psilocybin experiments have produced striking evidence for therapeutic uses of hallucinogens.